The Chemours Company account plan
Chemical solutions for industries
At a glance
Chemours makes refrigerants, titanium dioxide pigment and fluoropolymers, with $5,808 million of FY2025 net sales and about 5,700 employees.
The Chemours Company is a global performance-chemicals maker spun off from DuPont on July 1, 2015, selling refrigerants (Opteon, Freon), Ti-Pure titanium dioxide pigment and fluoropolymers (Teflon, Viton, Krytox, Nafion). It serves refrigeration and air conditioning, coatings, plastics, semiconductor, electronics, transportation and industrial customers: about 2,400 customers in about 110 countries from 28 major production facilities in eight countries. FY2025 net sales were $5,808 million, with a net loss attributable to Chemours of $(386) million driven by the New Jersey PFAS settlement. It had about 5,700 employees at end-2025 and is led by President and CEO Denise Dignam.
Business units
Thermal & Specialized Solutions (TSS)
about 36% of FY2025 net sales ($2,066 million)Refrigerants, thermal management, propellants, foam blowing agents and solvents; low-GWP Opteon refrigerants reached $1,264 million in 2025 on the U.S. AIM Act transition, with Adjusted EBITDA of $670 million (32% margin). Q3 2026 net sales fell 9% as the North American stationary AC aftermarket digested 2025 channel fill. Led by Joseph T. Martinko.
Titanium Technologies (TT)
about 42% of FY2025 net sales ($2,429 million)Ti-Pure TiO2 pigment for coatings, plastics and laminate papers from three plants with about 1.1 million metric tons per year of capacity, plus mineral sands mines in Florida and Georgia. Net sales fell 6% in 2025 and Adjusted EBITDA 52% to $145 million, but Q3 2026 net sales rose 11% on price increases. Michael Foley became President - TT in February 2026.
Advanced Performance Materials (APM)
about 22% of FY2025 net sales ($1,263 million)High-end fluoropolymers and advanced materials (Teflon, Viton, Krytox, Nafion) for semiconductors, electronics, data centers, transportation, energy and hydrogen. Net sales fell 5% in 2025 after the Washington Works outage and SPS Capstone exit; Q3 2026 net sales rose 8% to $337 million on data center and semiconductor demand. Led by Gerardo Familiar.
Performance Chemicals and Intermediates (Other Segment)
under 1% of FY2025 net sales ($50 million)A small remaining chemicals business reported outside the three main segments.
Strategic priorities
- Pathway to Thrive
- The strategy launched in 2024 has four pillars: operational excellence, enabling growth, portfolio management and strengthening the long term; management says no portfolio action is off the table, including transformational partnerships.
- AI infrastructure and liquid cooling
- Growth investments concentrate on data center cooling, next generation refrigerant and semiconductor fabrication; data center and semiconductor products approach nearly half of Performance Solutions, and Chemours launched Phazon two-phase cooling fluids.
- $1 billion EBITDA ambition
- Management targets at least $1 billion of annual adjusted EBITDA from the core businesses with free cash flow conversion exceeding 40%, without a date.
- Debt reduction
- Debt reduction is the capital priority: EUR280 million of the euro term loan was repaid in 2026, and net leverage is targeted below 4.2x at end-2026 and sustainably below 3x longer term.
- Resolve legacy PFAS liabilities
- Chemours reached the North Carolina settlement, the final New Jersey Judicial Consent Order and EPA and West Virginia DEP settlements in 2026, while cutting targeted process emissions 80% since 2018 toward a 99% goal by 2030.
Latest results
In Q3 2026 (quarter to September 30), net sales rose 3% to $1,540 million on price, and net income attributable to Chemours was $196 million ($1.29 per diluted share) against $46 million, helped by $150 million received under the PFAS Insurance MOU. Adjusted EBITDA was $200 million, at the high end of guidance. TT Adjusted EBITDA rose to $85 million from $25 million and APM to $24 million, while TSS fell 30% to $136 million. Over nine months the company had a net loss of $(107) million after a $307 million tax provision. The 2026 outlook was cut to net sales growth of around 2% and Adjusted EBITDA of $775-800 million, and management expects earnings growth in 2027.
Investments and deals
- Capex programme
- Capex fell to $213 million in 2025 from $360 million; 2026 capex is guided at $220-230 million, and 2027 capex is not expected to rise by a large amount.
- Kuan Yin site sale
- Ten parcels of the former Kuan Yin, Taiwan site were sold for about $360 million, producing a $316 million nine-month gain in 2026, with proceeds used to reduce debt.
- Phazon two-phase cooling launch
- Phazon is the first brand Chemours has launched, aimed at AI data centers; product trials rose 70% year over year and qualification work includes Samsung and hyperscalers.
- Refinancing
- $700 million of 2034 Notes issued in March 2026 redeemed the $495 million notes due 2027 and $188 million of the 2028 notes.
- 2026 Restructuring Program
- A company-wide restructuring under Pathway to Thrive produced $10 million of employee separation charges over the first nine months of 2026.
Challenges and risks
- Legacy PFAS liabilities
- Environmental remediation liabilities rose to $805 million at September 30, 2026 from $618 million, with accrued litigation of $553 million; about $1.1 billion remains under the $4 billion MOU cost-sharing cap.
- Refrigerant aftermarket slump
- After the 2025 AIM Act channel fill, management saw about a 25% drop in stationary AC aftermarket volume in 2026, with visibility returning toward the end of Q1 2027.
- TiO2 overcapacity and imports
- World TiO2 demand of about 7.3 million metric tons in 2025 compared with about 10 million metric tons of capacity; Chinese producers compete and Dignam says Chemours will defend the U.S. market.
- Leverage and credit rating
- Moody's cut Chemours to B1 from Ba3 in July 2026, and debt maturities include about $1,282 million in 2028.
- Plant disruptions and input costs
- Washington Works outages hit APM in 2025 and January 2026, and higher sulfur and raw material costs weighed on TSS and COGS.
What leadership says
“I want to be clear; no portfolio action is off the table where we see an opportunity to unlock a step change in value creation for our shareholders.”
“We expect Chemours to deliver earnings growth in 2027.”
“we will aggressively defend the U.S. market”
“a very strategic new market for us with significant long-term growth”
Where a supplier can help
- Data center go-to-market
- Tied to the AI infrastructure priority and the Phazon launch: Chemours must get specified across the value chain with hyperscalers and OEMs, creating needs for market intelligence, partner programmes and technical sales support.
- Lean operations and cost savings
- Tied to Pathway to Thrive's operational excellence pillar and the 2026 Restructuring Program: process improvement, maintenance and reliability tools help avoid outages like those at Washington Works.
- PFAS remediation and compliance
- Tied to the legacy PFAS challenge: expanded drinking water programmes and consent decree work at Washington Works and Chambers Works need environmental engineering, monitoring and emissions-abatement services.
- Working capital and treasury
- Tied to the debt reduction priority and free cash flow target: cash management, receivables and procurement solutions that lift free cash flow conversion support deleveraging.
- Pricing and channel analytics
- Tied to TiO2 price increases and the refrigerant aftermarket slump: demand sensing and pricing tools help manage channel inventory and defend share against imports.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like The Chemours Company?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Form 10-K for fiscal year 2025
- Chemours is a global performance-chemicals maker (spun off from DuPont/EID on July 1, 2015): refrigerants, titanium dioxide (TiO2) pigment and fluoropolymers, run as three segments - Thermal & Specialized Solutions (TSS), Titanium Technologies (TT) and Advanced Performance Materials (APM) - plus Performance Chemicals and Intermediates in Other Segment.
- FY2025 net sales were $5,808 million (2024: $5,782 million); net loss attributable to Chemours was $(386) million (2024: net income $69 million), driven by $270 million for the New Jersey PFAS settlement and a $181 million deferred-tax valuation allowance.
- TSS is the profit engine: net sales up 13% to $2,066 million and Adjusted EBITDA $670 million (32% margin), with Opteon refrigerants at $1,264 million (2024: $810 million) on the U.S. AIM Act transition to low-GWP refrigerants.
- TT (Ti-Pure TiO2) is in a downturn: net sales down 6% to $2,429 million, Adjusted EBITDA down 52% to $145 million (6% margin); APM net sales down 5% to $1,263 million, Adjusted EBITDA $108 million (9%), hit by the Washington Works outage and the SPS Capstone exit.
- Strategy is "Pathway to Thrive" (2024): Operational Excellence, Enabling Growth (data center cooling, next generation refrigerant, semiconductor fabrication), Portfolio Management, and Strengthening the Long Term (resolving legacy litigation, responsible manufacturing, advocacy).
- Capex fell to $213 million in 2025 (2024: $360 million) and is expected at $250-300 million in 2026; a ~$360 million sale of the former Kuan Yin, Taiwan site was signed in January 2026, with proceeds earmarked for debt reduction.
- Legacy PFAS liabilities dominate the risk profile: $618 million of environmental remediation liabilities and $484 million accrued litigation at end-2025, shared with DuPont and Corteva under the 2021 MOU (about $1.3 billion of the $4 billion cap remaining).
- About 5,700 employees (79% in the Americas), 28 major production facilities in eight countries, about 2,400 customers in about 110 countries; led by CEO Denise Dignam and CFO Shane Hostetter, with Michael Foley joining as President - Titanium Technologies in February 2026.
- Form 10-Q for the quarter ended September 30, 2026
- Q3 2026 (quarter to September 30, 2026): net sales $1,540 million, up 3% (price +5%, volume -2%); net income attributable to Chemours $196 million, diluted EPS $1.29 (Q3 2025: $46 million, $0.31).
- Nine months: net sales $4,512 million (flat), net loss $(107) million, mainly from a $307 million tax provision including a full valuation allowance on U.S. federal and state deferred tax assets.
- TSS weakened: Q3 net sales down 9% to $510 million and Adjusted EBITDA down 30% to $136 million (27% margin) as North American stationary AC aftermarket sales of Opteon blends fell against the AIM Act-driven Q3 2025.
- TT recovered on price: Q3 net sales up 11% to $680 million (price +10%), Adjusted EBITDA $85 million (13% margin) against $25 million a year earlier.
- APM Q3 net sales up 8% to $337 million on data center and semiconductor demand, Adjusted EBITDA $24 million (7%); nine-month volumes down 8% after the SPS Capstone exit.
- One-offs: $150 million received under the PFAS Insurance MOU (booked as an SG&A credit) and a $316 million nine-month gain on the sale of ten Kuan Yin, Taiwan land parcels.
- Balance sheet: $700 million of 2034 Notes issued in March 2026 to redeem the 2027 notes and part of the 2028 notes; EUR280 million of the euro term loan repaid in nine months; Moody's cut the rating to B1 from Ba3 in July 2026 with a stable outlook.
- PFAS exposure rose: environmental remediation liabilities $805 million (from $618 million at end-2025) after the 2026 Consent Decree at Washington Works and Chambers Works; accrued litigation $553 million; North Carolina settlement reached in September 2026.
- Chemours Q3 2026 earnings call transcript
- Q3 2026 Adjusted EBITDA was $200 million, "at the high end of our guidance range"; net sales up 3% on TT pricing and 26% growth in APM's Performance Solutions, offsetting softer TSS.
- 2026 outlook cut to net sales growth of around 2% and Adjusted EBITDA of $775-800 million; free cash flow conversion 15-20% with capex of $220-230 million; net leverage below 4.2x at end-2026.
- Q4 guidance: TSS Adjusted EBITDA $105-115 million, TT $60-65 million, APM $40-45 million; management says "We expect Chemours to deliver earnings growth in 2027."
- TSS: North American stationary AC aftermarket for Opteon blends remains weak after the AIM Act channel fill; visibility returns towards the end of Q1 2027; CFO reaffirms TSS as "a GDP-plus type business with margins above the 30% type range".
- TT: global TiO2 pricing up 10% year on year after three increases; Dignam: "we will aggressively defend the U.S. market" against Chinese imports.
- APM / AI infrastructure: data center and semiconductor products now approach nearly half of Performance Solutions; Dignam calls semiconductor and data center demand "so robust" that catching up on orders in 2027 is unlikely.
- Launch of Phazon, two-phase liquid cooling fluids for AI data centers - "the first brand that Chemours has launched"; a two-phase data center architecture could come "possibly in 2027".
- Balance sheet de-risking: North Carolina PFAS settlement, final New Jersey Judicial Consent Order, Kuan Yin land sale closed (final ~$56 million), EUR280 million of euro term loan repaid in 2026.
- Chemours Q2 2026 earnings call transcript
- Q2 2026 call (August 5, 2026), halfway through Pathway to Thrive: Dignam says "no portfolio action is off the table" where it can unlock "a step change in value creation", including "transformational partnerships".
- Target from the core businesses: "at least $1 billion of annual adjusted EBITDA, free cash flow conversion exceeding 40%"; liquid cooling and next-generation refrigerants are upsides to that case.
- 2026 guidance then: net sales up 1-5%, Adjusted EBITDA $775-825 million, capex $250-280 million, free cash flow conversion above 25%, net leverage around 3.8x by end-2026 (long-term goal below 3x).
- TSS: the 2025 AIM Act channel fill left the stationary aftermarket oversupplied; Dignam sees about a 25% drop in aftermarket volume this year, with recovery "picking back up" at the end of Q1 2027; about $65 million of 2025 sales were effectively pre-buy.
- TT: three TiO2 price increases since December 2025, about 5% year-to-date; Q3 Adjusted EBITDA guided to $70-80 million; mid-cycle TT floor "over 400" million per Hostetter.
- APM: Performance Solutions sales up 8%; AI infrastructure (data center, semiconductor, advanced electronics) is a high single-digit percentage of TSS + APM sales and over 40% of Performance Solutions.
- Two-phase liquid cooling: nominal sampling sales, product trials up 70% year over year; route to market is spec-in across the value chain (Samsung qualification, hyperscalers) and sales through OEMs.
- About $270 million of the 2028 euro term loan repaid in Q2 from Kuan Yin proceeds and organic cash; EPA and West Virginia DEP settlements reached.
Questions about The Chemours Company
What does Chemours do?
Chemours makes performance chemicals: Opteon and Freon refrigerants, Ti-Pure titanium dioxide pigment, and fluoropolymers such as Teflon, Viton, Krytox and Nafion for industrial, electronics and data center customers.
What is Chemours' revenue?
Net sales were $5,808 million in FY2025. In Q3 2026 net sales were $1,540 million, up 3%, and 2026 Adjusted EBITDA is guided at $775-800 million.
How many employees does Chemours have?
Chemours had about 5,700 employees at end-2025, 79% of them in the Americas.
Who leads Chemours?
Denise Dignam has been President and CEO since March 2024; Shane Hostetter has been CFO since July 2024.
What is Chemours' strategy?
Its Pathway to Thrive strategy combines cost reduction, growth in data center cooling, next generation refrigerant and semiconductor markets, portfolio reshaping and resolution of legacy PFAS litigation.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)